BRBI vs TROO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score, raising concerns about bankruptcy risk assessment. Despite a high ROE of 20.85% and a dividend yield of 21.16%, the stock appears overvalued relative to both the Graham Number ($6.63) and Intrinsic Value ($9.38), trading at $14.39. Profitability metrics are distorted by a 101.45% operating margin and zero gross/profit margins, suggesting non-operational income dominance. Coupled with negative earnings growth, high debt/equity of 18.65, and bearish technical trends, the fundamental outlook remains fragile.
TROO presents a high-risk profile characterized by a stable Piotroski F-Score of 4/9 but severe fundamental imbalances. While the company exhibits hyper-growth with 192.10% YoY revenue increase and maintains a debt-free balance sheet with high liquidity (Current Ratio 6.36), its profitability is disastrous, featuring a negative gross margin of -7.27% and a profit margin of -86.34%. The valuation is extreme, with a Price/Sales ratio of 24.58, which is unsustainable for the credit services industry. Despite recent price momentum, the lack of earnings and negative margins suggest the stock is trading on speculation rather than intrinsic value.
Compare Another Pair
Related Comparisons
BRBI vs TROO: Head-to-Head Comparison
This page compares BRBI BR Partners S.A. (BRBI) and TROOPS, Inc. (TROO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.